Eli Lilly and Company
Business & Industry
- Bayer and Salus Optima partner on AI-enabled healthy aging journey
- Pfizer announces topline Phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity
- Bayer and Hurdle launch precision health strategic partnership
- Bayer invests 130 million EUR in new production facility for innovative parenteral products
- Pfizer and Astellas' XTANDI® approved by U.S. FDA in earlier prostate cancer treatment setting
Research & Development
- The risk of cardiovascular disease can be reduced by eating more oily fish
- New technique efficiently offers insight into gene regulation
- A patch of protection against Zika virus
- Scientists uncover how fermented-food bacteria can guard against depression, anxiety
- AI may spare breast cancer patients unnecessary treatments
- Lidocaine may be able to kill certain cancer cells by activating bitter taste receptors
- Skin bacteria can save lives
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA approves first gene therapies to treat patients with sickle cell disease
- FDA approves first therapy for rare type of non-cancerous tumors
- First electronic product information (ePI) published for selected human medicines
- FDA approves first treatment for patients with rare inherited blood clotting disorder
- FDA takes action on updated mRNA COVID-19 vaccines to better protect against currently circulating variants